StockNews.AI
MRNA
StockNews.AI
141 days

Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults

1. Moderna's RSV vaccine mRESVIA approved in Australia for adults 60 and older. 2. This is the first non-COVID mRNA vaccine approved in Australia.

2m saved
Insight
Article

FAQ

Why Bullish?

Regulatory approval for mRESVIA expands Moderna's product portfolio, positioning it positively in the market. Historical data shows that approvals of new vaccines can often lead to stock price increases due to market optimism.

How important is it?

The approval of mRESVIA may have a significant impact on Moderna's sales and overall market perception, thus affecting investor sentiment.

Why Long Term?

This approval opens doors for future RSV market opportunities and potential international expansion, impacting Moderna's revenue growth over time.

Related Companies

NVAXPFEJNJ
CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older.1 mRESVIA's approval marks a significant milestone as it is the first mRNA vaccine in Australia approved for use against a disease beyond COVID-19. "We are pleased to receive regulatory approval for mRESVIA in Australia following the TGA's decision," said Stéphane Bancel, Chief Executive Officer of Moderna.

Related News